FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:747-750 February 15, 2007 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Rosenfeld, P. J. Related Article by Brown, D. M. PubMed Citation

To the Editor: The results of the MARINA (Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration) study and the ANCHOR (Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration) study (Oct. 5 issue)^1,2 show the remarkable and reassuring safety of ranibizumab in the treatment of neovascular age-related macular degeneration. We are concerned, however, by the low reported rate of arterial thromboembolic events in both ranibizumab groups (4.6% over a period of 2 years among patients receiving 0.3 mg or 0.5 mg) and sham injection (3.8%) in the . . . [Full Text of this Article]

This article has been cited by other articles:

• Zhang, X., Bao, S., Lai, D., Rapkins, R. W., Gillies, M. C. (2008). Intravitreal Triamcinolone Acetonide Inhibits Breakdown of the Blood-Retinal Barrier Through Differential Regulation of VEGF-A and Its Receptors in Early Diabetic Rat Retinas. Diabetes 57: 1026-1033 [Abstract] [Full Text]  
• Tan, J S L, Wang, J J, Liew, G, Rochtchina, E, Mitchell, P (2008). Age-related macular degeneration and mortality from cardiovascular disease or stroke. Br. J. Ophthalmol. 92: 509-512 [Abstract] [Full Text]